Wednesday , September 20 2017
Home / 2016 / April

Monthly Archives: April 2016

Diplomat to Acquire Oncology-Focused TNH Advanced Specialty Pharmacy

FLINT, Mich., April 28, 2016 /PRNewswire/ — Click here for supplemental information regarding the transaction. Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation’s largest independent specialty pharmacy, announced today that it has signed a definitive agreement to acquire Valley Campus Pharmacy, Inc., doing business as TNH Advanced Specialty Pharmacy (“TNH”), a leading …

Read More »

FDA Authorizes Quest’s Zika Test for Emergency Use

MADISON, N.J., April 28, 2016 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test). The test …

Read More »

New Gene Testing Technology Finds Cancer Risks ‘Hiding in Plain Sight’

A research team led by an award-winning genomicist at Western University has developed a new method for identifying mutations and prioritizing variants in breast and ovarian cancer genes, which will not only reduce the number of possible variants for doctors to investigate, but also increase the number of patients that …

Read More »

Making Precision Medicine A Reality: Genomics Researchers Unveil Road Map to Disease Origin

TUCSON, Ariz. – Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies – thanks to work by three computational biology research teams from the University of Arizona Health Sciences, University …

Read More »

AbbVie Acquires Cancer Drugmaker Startup Stemcentrx for up to $10.2 Billion

NORTH CHICAGO, Ill., April 28, 2016 /PRNewswire/ — AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced that it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell lung cancer (SCLC). Rova-T is a novel biomarker-specific therapy that is derived from cancer stem …

Read More »

FDA Approves Collegium’s Abuse-Deterrent Opioid Painkiller Xtampza ER

CANTON, Mass., April 26, 2016 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) approved Xtampza™ ER (oxycodone) extended-release (ER) capsules CII, a twice-daily, oxycodone medication for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for …

Read More »

AstraZeneca Sells Ironwood US Rights to its Gout Drug Zurampic

26 April 2016 AstraZeneca today announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic® (lesinurad). Zurampic was approved by the US Food and Drug Administration (FDA) in December 2015, in combination with a xanthine oxidase inhibitor (XOI), for the treatment …

Read More »

Celldex Initiates Phase 1/2 Study in Squamous Cell Lung Cancer

HAMPTON, N.J., April 27, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable stage IIIB or IV, gpNMB-expressing, advanced or metastatic squamous cell carcinoma (SCC) of the lung, who have …

Read More »

Talk Pays Off

Medication adherence continues to be an important topic in the health care world. Despite a greater understanding of the pitfalls surrounding patient adherence, there is still a far distance to go before the problem of adherence can be considered solved. To better understand barriers to adherence, a group of researchers …

Read More »